Queen’s Gambit Growth Capital (GMBT) Adds $21.5M to Swvl PIPE
by Nicholas Alan Clayton on 2022-02-02 at 2:45pm

Queen’s Gambit (NASDAQ:GMBT) has added $21.5 million to the PIPE for its combination with Dubai-based ride-hailer Swvl one day after terminating a previous forward-purchase agreement (FPA).

These additions bring the total PIPE proceeds to $121.5 million and include commitments from the European Bank for Reconstruction and Development (EBRD), Agility, Luxor Capital Group, Chimera, and Zain. This is still below the deal’s $185 million minimum cash condition, but Swvl may be motivated to waive this if it proves an impediment to close as it has already put some of the PIPE capital to work.

Of the total PIPE amount, $66.5 million came in the form of convertible note financing that Swvl has already received to accelerate its growth. The $45.5 million of these notes that were issued in 2021 will be automatically exchanged for shares in the combined company at $8.50 per share while the remaining $21 million that were issued in 2022 will be exchanged at $9.10 per share.

Queen’s Gambit’s terms include a crescent term set at $9.20, but we won’t know if that condition is triggered until after this deal closes. The exercise price for Queen’s Gambit warrants will only be adjusted if equity-linked instruments priced under $9.20 per share represent at least 60% of all equity funding going into the deal after redemptions.

As it stands now, such instruments do not represent 60% of that amount since the SPAC still has $345 million in trust for the time being. Queen’s Gambit would further have to trade with a VWAP below $9.20 for 20 days starting on the day prior to consummating the transaction for the warrants to be adjusted (it opened Wednesday trading at $9.85).

In other words, more would need to change in order for this to come into play and Queen’s Gambit has nearly a full year left on its clock.

Queen’s Gambit initially announced its $1.1 billion combination with Swvl on July 28. Dubai-based Swvl operates a shared ride-hailing service using minibuses as an urban transport solution as well as a B2B service.

 

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved